Sign In
Last checked at 
9 Oct 2009 10:14
ο»Ώ
|
FOR IMMEDIATE RELEASE |
9 OCTOBERΒ 2009 |
Β
ImmuPharma PLC
("ImmuPharma")
AppointmentΒ ofΒ JointΒ BrokerΒ
ImmuPharma PLCΒ (LSE: IMM) the specialist discovery and development pharmaceutical company is pleased to announce the appointment of NobleΒ & Company LimitedΒ ("Noble")Β as its joint broker with immediate effect.
Commenting on Noble's appointment, Richard Warr, Chairman of ImmuPharma said: "We are delighted to have a team asΒ committedΒ as Noble working with us. Over theΒ past months they have been instrumental inΒ attractingΒ blue-chip fundsΒ onto ImmuPharma's share register."
- Ends -
For further information please contact:Β
|
ImmuPharma PLC |
+44 20 7152 4080 |
|
Dimitri Dimitriou, Chief Executive OfficerΒ Richard Warr, Chairman |
|
|
Buchanan Communications |
+44 20 7466 5000 |
|
Lisa BaderoonΒ |
|
|
Panmure Gordon & Co Andrew Burnett Rakesh Sharma |
+44 151 243 0963 |
|
Noble & Company Limited |
+44Β 20 7763 2200 |
|
James Bromhead Sam Reynolds |
Notes to Editors
AboutΒ ImmuPharma PLC
ImmuPharma is a drug discovery and development group with its key operations inΒ LondonΒ and subsidiaries inΒ Mulhouse,Β FranceΒ andΒ Basle,Β Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus,Β 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders.Β
Its lead candidate for the treatment of Lupus, LupuzorTM,Β a chronic, life-threatening autoimmune disease,Β was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009
The company also has a strong proprietary and collaborative drug development pipeline.
Follow the stocks
